Therapeutic Intervention of Corticospinal Tract Sprouting after Unilateral Traumatic Brain Injury via METTL1-Mediated tRNA m7G Modification

share:

Brief intro:

  • Author: Zhenpeng Li, An Jiang, Bengang Qin, Jintao Fang, Xubo Li, Fanbin Gu, Wenting He, Liwei Yan, Jiantao Yang, Canbin Zheng, Qingtang Zhu & Honggang Wang
  • Journal: Molecular Neurobiology
  • Doi: https://www.doi.org/10.1007/s12035-025-05599-6
  • Publication Date: 2025/12/12

Products/Services used in the paper

Request Quote

Abstract

Corticospinal tracts (CST) from the contralateral side spontaneously sprouting into the denervated motor neurons in the impaired spinal hemicord allow the contralateral motor cortex to control the paralyzed limb, improving the impaired limb function after unilateral brain injury. However, the intrinsic potential for axon outgrowth in adults is limited, restricting the functional recovery through CST sprouting. While ribosomal RNA modification has been reported in regulating CST sprouting, the role of transfer RNA (tRNA) modifications remains unclear. Here, we investigated METTL1, the methyltransferase for tRNA m7G modification, as a potential regulator of CST sprouting. In a mouse model of unilateral traumatic brain injury, we found overexpression of METTL1 in contralesional corticospinal neurons improved motor function recovery and promoted CST sprouting. Mechanistically, METTL1 upregulates tRNA m7G modification level, which augments the translation efficiency of mRNAs associated with axon outgrowth, particularly those within the mTOR signaling pathway. Critically, pharmacological inhibition of mTOR signaling with rapamycin diminishes the beneficial effects of METTL1 overexpression on axon outgrowth and CST sprouting. Our findings reveal a novel role for METTL1-mediated tRNA m7G modification in promoting neural repair and identify a potential therapeutic strategy for enhancing recovery after unilateral brain injury.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download

Login

Don't have an account? Please register
Account*
Password*
Code*
Refresh
Forgot password?
Logging in indicates that you have read and accepted the Registration Agreement and User Agreement
Log in with other accounts

New User Registration

Already have an account?
First Name*
Middle Name
Last Name*
Organization*
Organization Type*
Country/State*
Email Address*
Set Password*
Confirm password*
Refferal Code*

Reset Password

Return to
Email*
Code*
New password*
Confirm password*

Google Account Binding

Organization*
Organization Type*
Country/State*